Professor Cluzeau was born in Bergerac in France. Heis MD, PhD in Hematology. He was resident in Nice hospital, research fellow in Mediterranean Center of Molecular Medecine, chief resident in Saint Louis Hospital (Paris), research fellow in Moffitt Cancer Center and Research Institute (Tampa), chief resident in Nice Hospital. He is Professor at Cote d’Azur University and Nice Hospital. He learns Hematology to student at medicine faculty of Nice and he train residents in hematology.
Current Research
Interested topics
2016 – Capacity to drive research, Nice Sophia Antipolis University, Nice, France
Membership
International collaborations
Editorships
Conference Organization
1. Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy. Prebet T, Cluzeau T, Park S, Sekeres MA, Germing U, Ades L, Platzbecker U, Gotze K, Vey N, Oliva E, Sugrue MM, Bally C, Kelaidi C, Ali NA, Fenaux P, Gore SD, Komrokji R. Oncotarget. 2017 Jun 14.doi: 10.18632/oncotarget.18477. [Epub ahead of print] PMID: 28645118
2. Early Response-Based Therapy Stratification Improves Survival in Adult Early Thymic Precursor Acute Lymphoblastic Leukemia: A Group for Research on Adult Acute Lymphoblastic Leukemia Study. Bond J, Graux C, Lhermitte L, Lara D, Cluzeau T, Leguay T, Cieslak A, Trinquand A, Pastoret C, Belhocine M, Spicuglia S, Lheritier V, Leprêtre S, Thomas X, Huguet F, Ifrah N, Dombret H, Macintyre E, Boissel N, Asnafi V. J ClinOncol. 2017 Jun 12: JCO2016718585. doi: 10.1200/JCO.2016.71.8585. [Epub ahead of print] PMID: 28605290
3. BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia. Vidal V, Robert G, Goursaud L, Durand L, Ginet C, Karsenti JM, Luciano F, Gastaud L, Garnier G, Braun T, Hirsch P, Raffoux E, Nloga AM, Padua RA, Dombret H, Rohrlich P, Ades L, Chomienne C, Auberger P, Fenaux P, Cluzeau T. Oncotarget. 2017 Apr 27.doi: 10.18632/oncotarget.17482. [Epub ahead of print] PMID: 28514758
4. Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy. Prebet T, Toma A, Cluzeau T, Sekeres MA, Vey N, Park S, Al Ali N, Sugrue MM, Komrokji R, Fenaux P, Gore SD. Oncotarget. 2017 Jun 6;8(23):37866-37874. doi: 10.18632/oncotarget.15200. PMID: 28184031
5. Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA. Wang L, Raffoux E, Thomas X, Yakoub-Agha I, Bouhris JH, de Botton S, Michallet M, Quoc SN, Chantepie S, Deconinck E, Caillot D, Turlure P, Vigouroux S, Pigneux A, Huynh A, Malfuson JV, Loschi M, Socie G, Dombret H, de la Tour RP, Cluzeau T. Leuk Res. 2017 Mar;54:12-16. doi: 10.1016/j.leukres.2017.01.002. Epub 2017 Jan 5. PMID: 28088653
6. The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Basiorka AA, McGraw KL, Eksioglu EA, Chen X, Johnson J, Zhang L, Zhang Q, Irvine BA, Cluzeau T, Sallman DA, Padron E, Komrokji R, Sokol L, Coll RC, Robertson AA, Cooper MA, Cleveland JL, O'Neill LA, Wei S, List AF. Blood. 2016 Dec 22;128(25):2960-2975. doi: 10.1182/blood-2016-07-730556. Epub 2016 Oct 13. PMID: 27737891
7. BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice. Hamouda MA, Jacquel A, Robert G, Puissant A, Richez V, Cassel R, Fenouille N, Roulland S, Gilleron J, Griessinger E, Dubois A, Bailly-Maitre B, Goncalves D, Mallavialle A, Colosetti P, Marchetti S, Amiot M, Gomez-Bougie P, Rochet N, Deckert M, Avet-Loiseau H, Hofman P, Karsenti JM, Jeandel PY, Blin-Wakkach C, Nadel B, Cluzeau T, Anderson KC, Fuzibet JG, Auberger P, Luciano F. J Exp Med. 2016 Aug 22;213(9):1705-22. doi: 10.1084/jem.20150983. Epub 2016 Jul 25. PMID: 27455953
8. Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype. Sallman DA, Cluzeau T, Basiorka AA, List A. Front Oncol. 2016 Jun 16;6:151. doi: 10.3389/fonc.2016.00151. eCollection 2016. Review. PMID: 27379212
9. Differentiation inducing factor 3 mediates its anti-leukemic effect through ROS-dependent DRP1-mediated mitochondrial fission and induction of caspase-independent cell death. Dubois A, Ginet C, Furstoss N, Belaid A, Hamouda MA, El Manaa W, Cluzeau T, Marchetti S, Ricci JE, Jacquel A, Luciano F, Driowya M, Benhida R, Auberger P, Robert G. Oncotarget. 2016 May 3;7(18):26120-36. doi: 10.18632/oncotarget.8319. PMID: 27027430
10. Risk factors and outcome of graft failure after HLA matched and mismatched unrelated donor hematopoietic stem cell transplantation: a study on behalf of SFGM-TC and SFHI. Cluzeau T, Lambert J, Raus N, Dessaux K, Absi L, Delbos F, Devys A, De Matteis M, Dubois V, Filloux M, Fort M, Hau F, Jollet I, Labalette M, Masson D, Mercier B, Pedron B, Perrier P, Picard C, Quainon F, Ramounau-Pigot A, Renac V, Van Endert P, Charron D, Peffault de la Tour R, Taupin JL, Loiseau P. BoneMarrow Transplant. 2016 May;51(5):687-91. doi: 10.1038/bmt.2015.351. Epub 2016 Feb 8. PMID: 26855158
11. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Sallman DA, Komrokji R, Vaupel C, Cluzeau T, Geyer SM, McGraw KL, Al Ali NH, Lancet J, McGinniss MJ, Nahas S, Smith AE, Kulasekararaj A, Mufti G, List A, Hall J, Padron E. Leukemia. 2015 Oct 30.doi: 10.1038/leu.2015.304. [Epub ahead of print] PMID: 26514544
12. TP53 and MDM2 single nucleotide polymorphisms influence survival in myelodysplastic syndromes. Cluzeau T, McGraw KL, Basiorka AA, Irvine BA, Zhang L, Epling Burnette PK, Rollinson DE, Mallo M, Sokol L, Sole F, Maciejewski J, List AF. Oncotarget. 2015 Oct 27;6(33):34437-45. doi: 10.18632/oncotarget.5255. PMID: 26416416
13. Management of myelodysplastic syndromes. Duchmann M, Fenaux P, Cluzeau T. Bull Cancer. 2015 Nov;102(11):946-57. doi: 10.1016/j.bulcan.2015.07.007. Epub 2015 Sep 26
14. Liposomal cytarabine, a good alternative to radiation therapy in prophylaxis or curative treatment of central nervous system involvement in Burkittleukaemia. Segot A, Raffoux E, Lengline E, Thieblemont C, Dombret H, Boissel N, Cluzeau T. Ann Hematol. 2015 Aug 18. [Epub ahead of print] PMID: 26280395
15. Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasm. Devillier R, Raffoux E, Rey J, Lengline E, Ronchetti AM, Sebert M, Boissel N, Robin M, Vey N, Kiladjian JJ, Dombret H, Cluzeau T. Br J Haematol. 2015 Jun 10.doi: 10.1111/bjh.13516. [Epub ahead of print]. PMID: 26061174
16. The PRKAA1/AMPKα1 pathway triggers autophagy during CSF1-induced human monocyte differentiation and is a potential target in CMML. Obba S, Hizir Z, Boyer L, Selimoglu-Buet D, Pfeifer A, Michel G, Hamouda MA, Gonçalvès D, Cerezo M, Marchetti S, Rocchi S, Droin N, Cluzeau T, Robert G, Luciano F, Robaye B, Foretz M, Viollet B, Legros L, Solary E, Auberger P, Jacquel A. Autophagy. 2015 Jun 1:0. [Epub ahead of print]. PMID: 26029847.
17. Novel fusion between the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with chronic myeloid leukemia-like neoplasm: undetectable residual disease after imatinib therapy. Cluzeau T, Cayuela JM, Maarek O, Migeon M, Cuccuini W, Raffoux E, Lippert E, Dombret H, Rea D. European Journal of Hematology: 2015 May 4. doi: 10.1111/ejh.12576. [Epub ahead of print]. PMID: 25941032.
18. Azacitidine for the treatment of relapsed and refractory AML in older patients. Itzykson R, Thépot S, Berthon C, Delaunay J, Bouscary D, Cluzeau T, Turlure P, Prébet T, Dartigeas C, Marolleau JP, Recher C, Plantier I, Stamatoullas A, Devidas A, Taksin AL, Guièze R, Caillot D, Vey N, Adès L, Ifrah N, Dombret H, Fenaux P, Gardin C. Leuk Res. 2015 Feb;39(2):124-30. doi: 10.1016/j.leukres.2014.11.009. Epub 2014 Nov 24. PMID: 25524177.
19. Azacitidine for the treatment of relapsed and refractory AML in older patients. Itzykson R, Thépot S, Berthon C, Delaunay J, Bouscary D, Cluzeau T, Turlure P, Prébet T, Dartigeas C, Marolleau JP, Recher C, Plantier I, Stamatoullas A, Devidas A, Taksin AL, Guièze R, Caillot D, Vey N, Adès L, Ifrah N, Dombret H, Fenaux P, Gardin C. Leuk Res. 2015 Feb;39(2):124-30. doi: 10.1016/j.leukres.2014.11.009. Epub 2014 Nov 24. PMID: 25524177 [PubMed - in process]
20. Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup. Hospital MA, Prebet T, Bertoli S, Thomas X, Tavernier E, Braun T, Pautas C, Perrot A, Lioure B, Rousselot P, Tamburini J, Cluzeau T, Konopacki J, Randriamalala E, Berthon C, Gourin MP, Recher C, Cahn JY, Ifrah N, Dombret H, Boissel N. Blood. 2014 Jul 8.pii: blood-2014-01-549212. [Epub ahead of print] PMID: 25006122 [PubMed - as supplied by publisher]
21. Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines. Cluzeau T, Dubois A, Jacquel A, Luciano F, Renneville A, Preudhomme C, Karsenti JM, Mounier N, Rohrlich P, Raynaud S, Mari B, Robert G, Auberger P. Oncotarget. 2014 Jun 30;5(12):4384-91. PMID: 24962689 [PubMed - in process]
22. Pediatric-Like Therapy for Adults with ALL. Dombret H, Cluzeau T, Huguet F, Boissel N. CurrHematolMalig Rep. 2014 Mar 30. [Epub ahead of print] PMID: 24682859 [PubMed - as supplied by publisher]
23. Early onset hypercholesterolemia induced by the second generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia. Rea D, Mirault T, Cluzeau T, Gautier JF, Guilhot F, Dombret H, Messas E. Haematologica. 2014 Mar 21. [Epub ahead of print]PMID: 24658819 [PubMed - as supplied by publisher]
24. Azacitidine in untreated acute myeloid leukemia: A report on 149 patients. Thépot S, Itzykson R, Seegers V, Recher C, Raffoux E, Quesnel B, Delaunay J, Cluzeau T, MarfaingKoka A, Stamatoullas A, Chaury MP, Dartigeas C, Cheze S, Banos A, Morel P, Plantier I, Taksin AL, Marolleau JP, Pautas C, Thomas X, Isnard F, Beve B, Chait Y, Guerci A, Vey N, Dreyfus F, Ades L, Ifrah N, Dombret H, Fenaux P, Gardin C; Groupe Francophone des Myélodysplasies (GFM), the Acute Leukemia French Association (ALFA); the GroupeOuest-Est des LeucémiesAiguës; Maladies du Sang (GOELAMS). Am J Hematol. 2014 Apr;89(4):410-6. doi: 10.1002/ajh.23654. Epub 2014 Feb 6. PMID: 24375487 [PubMed - in process]
25. Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine. Cluzeau T, Moreilhon C, Mounier N, Karsenti JM, Gastaud L, Garnier G, Re D, Montagne N, Gutnecht J, Auberger P, Fuzibet JG, Cassuto JP, Raynaud S. Blood Cancer J. 2013 Nov 1. PMID: 24185502 [PubMed]
26. Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with Azacitidine. Cluzeau T, Mounier N, Karsenti JM, Richez V, Legros L, Gastaud L, Garnier G, Re D, Montagne N, Gutnecht J, Gabriel Fuzibet J, Auberger P, Raynaud S, Cassuto JP. Am J Hematol. 2013 Sep. PMID: 23757315 [PubMed - indexed for MEDLINE]
27. How recent advances in high-risk myelodysplastic syndrome physiopathology may impact future treatments. Cluzeau T, Robert G, Jacquel A, Auberger P. CurrPharm Des. 2013. PMID: 23394086 [PubMed - in process]
28. [New tools and treatments in myelodysplastic syndromes]. Cluzeau T, Fenaux P. Rev Med Interne. 2013 Mar. PMID: 22766158 [PubMed - indexed for MEDLINE]
29. BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients. Cluzeau T, Robert G, Mounier N, Karsenti JM, Dufies M, Puissant A, Jacquel A, Renneville A, Preudhomme C, Cassuto JP, Raynaud S, Luciano F, Auberger P. Oncotarget. 2012 Apr. PMID: 22577154 [PubMed - indexed for MEDLINE]
30. The caspase 6 derived N-terminal fragment of DJ-1 promotes apoptosis via increased ROS production. Robert G, Puissant A, Dufies M, Marchetti S, Jacquel A, Cluzeau T, Colosetti P, Belhacene N, Kahle P, Da Costa CA, Luciano F, Checler F, Auberger P. Cell Death Differ. 2012 Nov. PMID: 22555455 [PubMed - indexed for MEDLINE]
31. Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness. Puissant A, Dufies M, Fenouille N, Ben Sahra I, Jacquel A, Robert G, Cluzeau T, Deckert M, Tichet M, Chéli Y, Cassuto JP, Raynaud S, Legros L, Pasquet JM, Mahon FX, Luciano F, Auberger P. J Mol Cell Biol. 2012 Aug. PMID: 22467682 [PubMed - indexed for MEDLINE]
32. Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells. Dufies M, Jacquel A, Belhacene N, Robert G, Cluzeau T, Luciano F, Cassuto JP, Raynaud S, Auberger P. Oncotarget. 2011 Nov. PMID: 22141136 [PubMed - indexed for MEDLINE]
33. Mechanism of action of the multikinase inhibitor Foretinib. Dufies M, Jacquel A, Robert G, Cluzeau T, Puissant A, Fenouille N, Legros L, Raynaud S, Cassuto JP, Luciano F, Auberger P. Cell Cycle. 2011 Dec 1. PMID: 22101270 [PubMed - indexed for MEDLINE]
34. Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia. Thépot S, Lainey E, Cluzeau T, Sébert M, Leroy C, Adès L, Tailler M, Galluzzi L, Baran-Marszak F, Roudot H, Eclache V, Gardin C, de Botton S, Auberger P, Fenaux P, Kroemer G, Boehrer S. Cell Cycle. 2011 Jul 15. PMID: 21654193 [PubMed - indexed for MEDLINE]
35. Azacitidine-resistant SKM1 myeloid cells are defective for AZA-induced mitochondrial apoptosis and autophagy. Cluzeau T, Robert G, Puissant A, Jean-Michel K, Cassuto JP, Raynaud S, Auberger P. Cell Cycle. 2011 Jul 15. PMID: 21654192 [PubMed - indexed for MEDLINE]
36. New sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem-cell transplantation in very high-risk acute myeloid leukemia. Cluzeau T, De Matteis M, Mounier N, Mannone L, Gratecos N, Ticchioni M, Thyss A, Raynaud S, Cassuto JP, Sirvent A. Am J Hematol. 2011 Jul. PMID: 21509800 [PubMed - indexed for MEDLINE]
37. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O, Quesnel B, Vey N, Gelsi-Boyer V, Raynaud S, Preudhomme C, Adès L, Fenaux P, Fontenay M; Groupe Francophone des Myelodysplasies (GFM). Leukemia. 2011 Jul. PMID: 21494260 [PubMed - indexed for MEDLINE]
38. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Thepot S, Itzykson R, Seegers V, Raffoux E, Quesnel B, Chait Y, Sorin L, Dreyfus F, Cluzeau T, Delaunay J, Sanhes L, Eclache V, Dartigeas C, Turlure P, Harel S, Salanoubat C, Kiladjian JJ, Fenaux P, Adès L; Groupe Francophone des Myelodysplasies (GFM). Blood.2010 Nov 11. PMID: 20664061 [PubMed - indexed for MEDLINE]
39. [Patients and the Web]. Cluzeau T, Mounier N. Bull Cancer. 2010 Oct. PMID: 20663740 [PubMed - indexed for MEDLINE]
40. CBFA2T2 and C20orf112: two novel fusion partners of RUNX1 in acute myeloid leukemia. Guastadisegni MC, Lonoce A, Impera L, Di Terlizzi F, Fugazza G, Aliano S, Grasso R, Cluzeau T, Raynaud S, Rocchi M, Storlazzi CT. Leukemia. 2010 Aug. PMID: 20520637 [PubMed - indexed for MEDLINE]
41. [Histone deacetylase inhibitors: highlight on epigenetic regulation]. Pécuchet N, Cluzeau T, Thibault C, Mounier N, Vignot S. Bull Cancer. 2010 Aug. PMID: 20483706 [PubMed - indexed for MEDLINE]
42. [Implications of ALK (anaplastic lymphoma kinase) in oncohematology]. Cluzeau T, Pécuchet N, Mounier N, Vignot S. Bull Cancer. 2010 Aug. PMID: 20483705 [PubMed - indexed for MEDLINE]
43. Pneumoblastoma: a rare lung tumour occurring as a long-term complication after allogeneic haematopoietic cell transplantation. Cluzeau T, Sirvent A, Lassalle S, Mouroux J, Mounier N. Bone Marrow Transplant. 2010 Jan. PMID: 19430497 [PubMed - indexed for MEDLINE